Positive outcome of the prespecified interim futility analysis for Ph 2b ASCEND trial of LSTA1 + SOC in patients with 1L mPDAC announced September 13, 2023
Datopotamab deruxtecan plus Imfinzi showed promising clinical activity in the 1L advanced NSCLC setting in TROPION-Lung04 Phase Ib trial September 13, 2023
Tagrisso plus chemotherapy extended mPFS by nearly 9 months in EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial September 13, 2023
Phase III ALINA study of Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) September 6, 2023
FAILED TRIAL: Ph 3 INNOVATE-3 trial of TTFields + paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of OS September 6, 2023
Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors Announced September 6, 2023
Positive Results from Ph 3 CONTACT-02 Trial of Cabozantinib + Atezolizumab in metastatic CRPC Announced September 6, 2023
Retevmo® (selpercatinib) Demonstrates Superior PFS Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer September 6, 2023
FAILED TRIAL: Phase 3 LEAP-010 Trial of LENVIMA + KEYTRUDA in Patients With Certain Types of Recurrent or mSCCHN unlikely to meet primary endpoint of OS September 6, 2023
Ph 3 Trial of TUKYSA + ado-trastuzumab emtansine Meets Primary Endpoint of PFS in Patients with Previously Treated HER2+ve Metastatic Breast Cancer August 23, 2023
WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced RCC August 23, 2023
First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy Announced August 23, 2023
Data Highlighting Clinical Efficacy & Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in “Cancer Discovery” August 23, 2023
Retevmo® (selpercatinib) Demonstrated Superior PFS vs a PD-1 Inhibitor + Chemo for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive NSCLC August 9, 2023
FAILED TRIAL: Ph 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer failed to meet primary endpoint of PFS improvement August 9, 2023
Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization Announced August 2, 2023
UGN-102 Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials in NMIBC patients August 2, 2023
In CARES 310 trial, camrelizumab + rivoceranib statistically prolonged OS and PFS and improved ORR versus sorafenib in uHCC August 2, 2023
Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma August 2, 2023
Enhertu demonstrated clinically meaningful PFS and OS across multiple HER2-expressing advanced solid tumours in DESTINY-PanTumor02 Phase II trial August 2, 2023
Ph 3 KEYNOTE-756 Trial Met Primary Endpoint of pCR Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer August 2, 2023
KEYTRUDA + Trastuzumab + Chemo Met Primary Endpoint of PFS as 1L Treatment in Patients With HER2-Positive Advanced GEJ Adenocarcinoma July 27, 2023
2nd Positive Interim Trial Data Readout announced in R/R mCRC in Ph 1b/2a IMX-110 IMMINENT-01 Trial July 27, 2023
